As fresh specimens of BLCA can be acquired after satisfying the need for diagnosis, we can attempt to develop an optimized and simplified procedure for tumor slices and various 3D culture systems to mimic the in vivo tumor microenvironment for precise prediction of the sensitivity and potential resistance to CDK4/6 inhibitors in the future. The gene discussed is CDK4; the disease is bladder transitional cell carcinoma.